The third ongoing vaccine, Bharat Biotech’s Covaxin, which is being developed in collaboration with the Indian Council for Medical Research (ICMR), is simultaneously undergoing Phase 3 human trials at 22 sites in India with around 26,000 volunteers. .
According to a senior company official, it will be at least 60 percent effective based on previous test results.
Vaccine release, dry run
On December 31, the Center had asked all states and territories in the Union to prepare for the launch of the COVID-19 vaccine, and a nationwide trial would be conducted on January 2.
The objectives of the trial would be to “assess the operational feasibility in using the Co-WIN application in the field environment, test the links between planning and implementation, and identify challenges and guide the way forward before actual implementation” , a press release from the government stated.
The activity will also focus on difficult terrain and regions with little logistical support.
The trial in the states of Assam, Andhra Pradesh, Punjab and Gujarat concluded on December 29 and all participating states expressed satisfaction with the operational approach and the help of IT platforms to ensure the transparency and monitoring of the processes of inoculation.
.
